CABINET Trial: Results

Video content above is prompted by the following:

CABINET Trial Results

Key Themes:

• Progression-Free Survival (PFS) as Primary End Point:
• PFS is an agreed-upon end point by an NCI task force for NETs

• Appropriate due to generally longer overall survival in NETs compared with other metastatic solid tumors

• PFS serves as a surrogate for benefit and possibly overall survival
• Extrapancreatic Cohort Results:
• PFS: 8.4 months (cabozantinib) vs 3.9 months (placebo); statistically significant

• Overall survival: 21.9 months vs 19.7 months; not statistically significant

• 33% crossed over from placebo to cabozantinib
• Pancreatic Cohort Results:
• PFS: 13.8 months (cabozantinib) vs 4.4 months (placebo); more pronounced difference

• Overall survival: 40 months vs 31.1 months; not statistically significant

• 41% crossed over from placebo to cabozantinib
• Safety Profile:
• No new safety signals identified

• Two-thirds of patients required dose reduction

• Average daily dose was just under 40 mg per day in both cohorts

Notable Insights:

Dr Halfdanarson observed that the more pronounced PFS benefit in pancreatic NETs was not surprising, as these tumors have historically been responsive to VEGF-directed therapies like sunitinib.